Back

Effectiveness and safety of Zoledronic acid in the treatment of osteoporosis

Summaries 3 min 4

Font Size

Created On: 19/02/2020

Effectiveness and safety of Zoledronic acid in the treatment of osteoporosis

The effectiveness of current treatments for osteoporosis is limited by poor patient compliance.

See All

Key take away

Zoledronic acid or zoledronate (ZA) is a bisphosphonate drug which is given intravenously to treat some bone diseases. This study provides valuable insights into the use of ZA in real-world settings. This treatment with once-yearly dosing of ZA improves adherence and clinical outcomes in patients with osteoporosis.

Background

The effectiveness of current treatments for osteoporosis is limited by poor patient compliance. However, a favorable dosing regimen of zoledronic acid (ZA) has the potential to improve patient compliance and thus clinical outcomes.

Method

The author conducted a retrospective analysis to examine adherence to and the antiosteoporotic effects of a once-yearly infusion of 5 mg of ZA in Taiwanese patients with osteoporosis for up to 48 months. Five men and 149 postmenopausal women (mean age, 77.1 years) were included. Prior to ZA treatment, 66.2% of patients had fractures; most patients discontinued previous treatments due to compliance or convenience issues. Approximately 85% of patients received at least 2 infusions of ZA.

Result

Following ZA treatment, bone mineral density improved from baseline at 12 months (11% from baseline; P=.01) and 48 months (20.7% from baseline; P=.009). In addition, there was a significant reduction in mean beta-C-telopeptide at all-time points from 12 (P<.001) to 36 months (P=.010). New clinical fractures occurred in 16 (10.4%) patients, of which 12 patients experienced a single fracture. Zoledronic acid had an acceptable safety profile; no adverse events were considered to be drug related. Treatment with ZA improved bone health by enhancing bone mineral density and reducing bone turnover, even in high-risk patients.